MedTrace Logo

The FARAPULSE PersAFOne III Trial for the Treatment of Persistent Atrial Fibrillation

NCT05272852 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2025-01-08

Study results available
· View outcomes & findings →

Summary

The objective of this safety and feasibility study is to assess whether the endocardial creation of electrically nonconductive lesions via PEF catheter ablation applied using the FARAPULSE Pulsed Field Ablation System Plus-PersAF is a feasible and safe treatment for PersAF and associated AFL

Conditions

  • Persistent Atrial Fibrillation

Interventions

DEVICE

FARAPULSE™ Pulsed Field Ablation System Plus

Ablation using FARAPULSE™ Pulsed Field Ablation System Plus

Sponsors & Collaborators

  • Boston Scientific Corporation

    lead INDUSTRY

Principal Investigators

  • Petr Neuzil · Nemocnice Na Homolce (homolka)

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-02-03
Primary Completion
2024-02-09
Completion
2024-02-09
FDA Device
Yes

Countries

  • Czechia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05272852 on ClinicalTrials.gov